Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds
Capricor Therapeutics jumped 7.6% to $30.01 early Monday after the company scheduled its fourth-quarter and full-year results for March 12, putting deramiocel—the company’s experimental treatment for Duchenne muscular dystrophy—back in focus. Duchenne is a genetic disorder that causes progressive muscle loss. Capricor plans to publish results after Thursday’s close and will hold its conference call at 4:30 p.m. ET. Timing is key here: Capricor is working to get U.S. approval back on track for deramiocel in Duchenne-related cardiomyopathy after the FDA rejected it in July. The company plans to showcase full Phase 3 results at the Muscular Dystrophy Association meeting on March 11, and as of February, said it had already submitted the complete HOPE-3 study report as part of its biologics license application, or BLA—the formal step for approval.
